SomaLogic, Inc. revised revenue guidance for the year ended December 31, 2021. Preliminary, unaudited revenue for the full year 2021 is expected to exceed $79 million, the upper end of the company's previously raised 2021 revenue guidance range, representing over 41% year-over-year revenue growth.
Standard BioTools Inc.
Equities
SLGC
US83444K1051
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+24.74% | 47.54B | |
-0.47% | 41.96B | |
+46.11% | 41.55B | |
+25.40% | 30.36B | |
+17.96% | 27.61B | |
-4.47% | 28.7B | |
+50.73% | 14.7B | |
+42.56% | 13.51B | |
+1.46% | 12.34B |